Nova Mentis Life Science Corp. has formed a tactical partnership with KGK Science Inc. to develop its psilocybin drug portfolio in Canada. Both Companies plan to jointly submit the Health Canada clinical trial application.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | 0.00% | +50.00% | -25.00% |
1st Jan change | Capi. | |
---|---|---|
-25.00% | 1.63M | |
+1.51% | 42.75B | |
+48.32% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NOVA Stock
- News Nova Mentis Life Science Corp.
- Nova Mentis Life Science Corp. Forms A Tactical Partnership with KGK Science Inc. to Develop Its Psilocybin Drug Portfolio in Canada